Literature DB >> 31199236

Another dimension to the understanding of local therapy for metastatic prostate cancer.

Michael Leveridge, Robert J Hamilton1.   

Abstract

Entities:  

Year:  2019        PMID： 31199236      PMCID： PMC6570604          DOI： 10.5489/cuaj.6049

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  7 in total

1.  Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8.

Authors:  André N Vis; Liselotte M S Boevé
Journal:  Eur Urol       Date:  2019-01-04       Impact factor: 20.096

2.  Radical Treatment of the Primary Tumor in Metastatic Bladder Cancer: Potentially Dangerous Findings From Observational Data.

Authors:  Christopher M Booth; Safiya Karim; Yingwei Peng; D Robert Siemens; Kelly Brennan; William J Mackillop
Journal:  J Clin Oncol       Date:  2017-12-13       Impact factor: 44.544

Review 3.  Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer.

Authors:  Ganna Chornokur; Kyle Dalton; Meghan E Borysova; Nagi B Kumar
Journal:  Prostate       Date:  2010-12-28       Impact factor: 4.104

4.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Christopher J Sweeney; Yu-Hui Chen; Michael Carducci; Glenn Liu; David F Jarrard; Mario Eisenberger; Yu-Ning Wong; Noah Hahn; Manish Kohli; Matthew M Cooney; Robert Dreicer; Nicholas J Vogelzang; Joel Picus; Daniel Shevrin; Maha Hussain; Jorge A Garcia; Robert S DiPaola
Journal:  N Engl J Med       Date:  2015-08-05       Impact factor: 91.245

5.  The effect of race on survival after local therapy in metastatic prostate cancer patients.

Authors:  Elio Mazzone; Marco Bandini; Felix Preisser; Sebastiano Nazzani; Zhe Tian; Firas Abdollah; Denis Soulieres; Markus Graefen; Francesco Montorsi; Shahrokh Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz
Journal:  Can Urol Assoc J       Date:  2019-06       Impact factor: 1.862

6.  Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

7.  Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Authors:  Christopher C Parker; Nicholas D James; Christopher D Brawley; Noel W Clarke; Alex P Hoyle; Adnan Ali; Alastair W S Ritchie; Gerhardt Attard; Simon Chowdhury; William Cross; David P Dearnaley; Silke Gillessen; Clare Gilson; Robert J Jones; Ruth E Langley; Zafar I Malik; Malcolm D Mason; David Matheson; Robin Millman; J Martin Russell; George N Thalmann; Claire L Amos; Roberto Alonzi; Amit Bahl; Alison Birtle; Omar Din; Hassan Douis; Chinnamani Eswar; Joanna Gale; Melissa R Gannon; Sai Jonnada; Sara Khaksar; Jason F Lester; Joe M O'Sullivan; Omi A Parikh; Ian D Pedley; Delia M Pudney; Denise J Sheehan; Narayanan Nair Srihari; Anna T H Tran; Mahesh K B Parmar; Matthew R Sydes
Journal:  Lancet       Date:  2018-10-21       Impact factor: 79.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.